Korjuny

Catumaxomab, the active ingredient in Korjuny, is a monoclonal antibody (bispecific) presented as a sterile solution for intraperitoneal use. It is employed to manage malignant ascites associated with EpCAM‑positive peritoneal carcinomatosis in adult cancer patients by facilitating immune‑mediated tumor cell destruction.

GNH USA supplies Korjuny as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Korjuny is indicated for malignant ascites associated with EpCAM‑positive peritoneal carcinomatosis, a condition within the peritoneal cancer disease family.

- Malignant ascites: reduces fluid accumulation and improves patient comfort. - Peritoneal carcinomatosis: targets and eliminates EpCAM‑expressing tumor cells within the peritoneal cavity. - Quality of life: helps control symptoms related to ascitic buildup in affected patients.

Common Side Effects: - Fever: transient elevation of body temperature after administration. - Abdominal pain: discomfort localized to the peritoneal area. - Nausea and vomiting: gastrointestinal upset occurring shortly after dosing. - Fatigue: generalized tiredness experienced during the treatment course.

Serious or Rare Side Effects: - Cytokine release syndrome: severe systemic inflammatory response requiring medical intervention. - Hypotension: significant drop in blood pressure that may need monitoring. - Severe allergic reactions: including anaphylaxis, urticaria or angioedema.

Precautions should be observed when using Korjuny to minimize risks and ensure optimal therapeutic outcomes.

- Cytokine release monitoring: observe patients for signs of systemic inflammation during and after infusion. - Liver function assessment: evaluate hepatic enzymes before and during therapy. - Immunosuppression caution: avoid use in patients with severe immunodeficiency. - Cardiac disease awareness: monitor cardiovascular status in patients with pre‑existing heart conditions. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions must be considered to avoid compromising safety or efficacy.

Major Interactions (Avoid): - Concurrent immunomodulatory antibodies: may increase risk of severe immune reactions. - Live vaccines: contraindicated due to immunosuppressive effects. - High‑dose corticosteroids: can diminish therapeutic activity.

Moderate Interactions (Monitor Closely): - Cytotoxic chemotherapy agents: monitor for additive toxicity. - Antibiotics affecting gut flora: may alter infection risk. - Anticoagulants: observe for bleeding tendencies.